GCV Symposium
Skip Content

17 February 2017

Rhythm reaches mezzanine stage to raise $41m

Pfizer and Ipsen returned to reinvest in the metabolic disorder treatment developer, which has now raised $114m altogether.

Author: Robert Lavine, News Editor

US-based peptide therapeutics developer Rhythm closed a $41m mezzanine round yesterday that included pharmaceutical companies Pfizer and Ipsen, the former participating through its Pfizer Venture Investments unit.